Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau

Molecular Neurodegeneration

Volumn 2, Issue 1, 2007, Pages

  Santa Maria, Ismael ^a   Hernández, Félix ^a   Del Rio, Joaquín ^b,c   Moreno, Francisco J ^a   Avila, Jesús ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35748977086     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-2-17     Document Type: Article

References (51)

1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985, 82:4245-9.
2. M Goedert: Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Land B Biol Sci 1999, 354:1101-18
3. Kjellen L, Llndahl U: Proteoglycans: structures and interactions. Annu Rev Biochem 1991, 60:443-75.
4. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA: Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 1996, 383:550-3.
5. Perez M, Valpuesta JM, Medina M, Montejo de Garcini E, Avila J: Polymerization of tau into filaments in the presence of heparin: the minimal sequence required fortau-tau interaction. J Neurochem 1996, 67:1 183-90.
6. Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG: An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 1994, 12:219-34.
7. Snow AD, Lara S, Nochlin D, Wight TN: Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease. Acta Neuropathol (Berl) 1989, 78:113-23.
8. Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Wight TN: Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Am J Pathol 1990, 137:1253-70.
9. Small DH, Williamson T, Reed G, Clarris H, Beyreuther K, Masters CL, Nurcombe V: The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Ann N Y Acad Sci 1996, 777:316-21.
10. J Avila, ALS Colaço: The role of sulfated glycosaminoglycans in Alzheimer.s disease: a hypothesis. Alzheimer's Research 1997,3:77-81
11. Castillo GM, Lukito W, Wight TN, Snow AD: The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 1999, 72:1681-7.
12. Arrasate M, Perez M, Valpuesta JM, Avila J: Role of glycosaminoglycans in determining the helicity of paired helical filaments. Am J Pathol 1997, 151:1115-22.
13. DeWitt DA, Silver J, Canning DR, Perry G: Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol 1993, 121:149-52.
14. DH Small, SS Mok, TG Williamson, V Nurcombe: Role of proteoglycans in neural development, regeneration, and the aging brain, j Neurochem 1996, 67:889-99
15. Perry G, Siedlak SL, Richey P, Kawai M, Cras P, Kalaria RN, Galloway PG, Scardina JM, Cordell B, Greenberg BD, et al.: Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease. J Neurosa 1991, 11:3679-83.
16. Gupta-Bansal R, Frederickson RC, Brunden KR: Proteoglycanmediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J Biol Chem 1995, 270:18666-71.
17. McLaurin J, Fraser PE: Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions. Eur J Biochem 2000, 267:6353-61.
18. Fraser PE, Nguyen JT, Chin DT, Kirschner DA: Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 1992, 59:1531-40.
19. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-6.
20. JA Hardy, GA Higgins: Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-5;
21. S Oddo, V Vasilevko, A Caccamo, M Kitazawa, D Cribbs, F Laferla: Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. Journal of Biological Chemistry 2006
22. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG: Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosa 2004, 24:4181-6.
23. Aisen PS: The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs 2005, 19:989-96.
24. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, et al.: Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiology of Aging 2006.
25. Aisen PS, Mehran M, Poole R, Lavoie I, Gervais F, Laurin J, Briand R, Garceau D: Clinical data on Alzhemed after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Neurobiology of Aging 2004, 25:.
26. Gervais F: Glycosaminoglycans mimetics: Potential to modify underlying disease process in Alzheimer's disesase. Neurobiology of Aging 2004, 25(S1):S11-S12.
27. Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, McLaughlin R, Morissette C, Paquette J: Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001, 8(Suppl 1):28-35.
28. Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-93.
29. Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB: Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol 2007, 9:139-48.
30. Avila J, Dominguez J, Diaz-Nido J: Regulation of microtubule dynamics by microtubule-associated protein expression and phosphorylation during neuronal development. Int J Dev Biol 1994, 38:13-25.
31. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S: Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-10.
32. Santa-Maria I, Perez M, Hernandez F, Avila J, Moreno FJ: Characteristics of the binding of thioflavin S to tau paired helical filaments. J Alzheimers Dis 2006, 9:279-85.
33. Sharma VM, Litersky JM, Bhaskar K, Lee G: Tau impacts on growth-factor-stimulated actin remodeling. J Cell Sci 2007, 120:748-57.
34. Yu JZ, Rasenick MM: Tau associates with actin in differentiating PC 12 cells. Faseb J 2006, 20:1452-61.
35. Goode BL, Denis PE, Panda D, Radeke MJ, Miller HP, Wilson L, Feinstein SC: Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol Biol Cell 1997, 8:353-65.
36. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI: C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 2000, 113(Pt 21):3737-45.
37. Gamblin TC, Berry RW, Binder LI: Tau polymerization: role of the amino terminus. Biochemistry 2003, 42:2252-7.
38. Brandt R, Leger J, Lee G: Interaction of tau with the neural plasma membrane mediated by tau's ammo-terminal projection domain. J Cell Biol 1995, 131:1327-40.
39. Perez M, Arrasate M, Montejo De Garcini E, Munoz V, Avila J: In vitro assembly of tau protein: mapping the regions involved in filament formation. Biochemistry 2001, 40:5983-91.
40. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, SatoYoshitake R, Takei Y, Noda T, Hirokawa N: Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369:488-91.
41. Diaz-Nido J, Wandosell F, Avila J: Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 2002, 23:1323-32.
42. Woods AG, Cribbs DH, Whittemore ER, Cotman CW: Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res 1995, 697:53-62.
43. SJ Pollack, Sadler, II, SR Hawtin, VJ Tailor, MS Shearman: Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC 12 cells. Neurosci Lett 1995, 184:113-6
44. Leveugle B, Ding W, Laurence F, Dehouck MP, Scanameo A, Cecchelli R, Fillit H: Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J Neurochem 1998, 70:736-44.
45. Z Scholefield, EA Yates, G Wayne, A Amour, W McDow-ell, JE Turnbull: Heparan sulfate regulates amyloid precursor protein processing by BACEI, the Alzheimer's beta-secretase. J Cell Biol 2003, 163:97-107
46. Bruckner G, Hausen D, Hartig W, Drlicek M, Arendt T, Brauer K: Cortical areas abundant in extracellular matrix chondroitin sulphate proteoglycans are less affected by cytoskeletal changes in Alzheimer's disease. Neuroscience 1999, 92:791-805.
47. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS: Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978, 38:3751-7.
48. Banker GA, Cowan WM: Rat hippocampal neurons in dispersed cell culture. Brain Res 1977, 126:397-42.
49. Vallee RB: A taxol-dependent procedure for the isolation of microtubules and microtubule-associated proteins (MAPs). J Cell Biol 1982, 92:435-42.
50. Mattson MP, Barger SW, Begley JG, Mark RJ: Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol 1995, 46:187-216.
51. Crowther RA, Olesen OF, Smith MJ, Jakes R, Goedert M: Assembly of Alzheimer-like filaments from full-length tau protein. FESS Lett 1994, 337:135-8.